HRV-CV: A Digital Biomarker for Age, Sex, and Behavior 11/30/25

Welcome to Cardiology Today – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like digital biomarker and wild-type amyloid. Key takeaway: HRV-CV: A Digital Biomarker for Age, Sex, and Behavior. Article Links: Article 1: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. (European journal of heart failure) Article 2: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. (European journal of heart failure) Article 3: Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling. (European heart journal. Cardiovascular Imaging) Article 4: Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex. (American journal of physiology. Heart and circulatory physiology) Article 5: Mid- and Late-term Left Ventricular Diastolic Function After the Ross Procedure. (Pediatric cardiology) Full episode page: https://podcast.explainheart.com/podcast/hrv-cv-a-digital-biomarker-for-age-sex-and-behavior-11-30-25/ Featured Articles Article 1: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. Journal: European journal of heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41317156 Summary: Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations. Article 2: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. Journal: European journal of heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41317156 Summary: Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations. Article 3: Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling. Journal: European heart journal. Cardiovascular Imaging PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41299774 Summary: The left atrioventricular ratio, defined as the ratio of maximal Left Atrial End-Systolic Volume to Left Ventricular End-Diastolic Volume, provides valuable context for cardiac remodeling assessment. This echocardiography-based measure aids in distinguishing between physiological and pathological cardiac changes. It addresses the critical need to consider the interdependence of left atrial and left ventricular remodeling, a relationship often overlooked in standard clinical practice. Article 4: Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex. Journal: American journal of physiology. Heart and circulatory physiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41309064 Summary: The heart rate variability coefficient of variation, an index of day-to-day cardiac autonomic fluctuation, functions as a scalable digital biomarker. This biomarker reliably reflects behavior and exhibits variations according to both age and sex. It offers significant potential for behavioral monitoring and health risk stratification in diverse populations. Article 5: Mid- and Late-term Left Ventricular Diastolic Function After the Ross Procedure. Journal: Pediatric cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41313350 Summary: Long-term ventricular mechanics following the Ross procedure for congenital aortic valve disease are not well understood. This procedure, a common surgical option, requires further investigation into its mid- and late-term effects on left ventricular diastolic function. Understanding these long-term functional characteristics is crucial, particularly when comparing outcomes to other surgical repairs for congenital heart lesions. Transcript Today’s date is November 30, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations. Article number two. Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations. Article number three. Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling. The left atrioventricular ratio, defined as the ratio of maximal Left Atrial End-Systolic Volume to Left Ventricular End-Diastolic Volume, provides valuable context for cardiac remodeling assessment. This echocardiography-based measure aids in distinguishing between physiological and pathological cardiac changes. It addresses the critical need to consider the interdependence of left atrial and left ventricular remodeling, a relationship often overlooked in standard clinical practice. Article number four. Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex. The heart rate variability coefficient of variation, an index of day-to-day cardiac autonomic fluctuation, functions as a scalable digital biomarker. This biomarker reliably reflects behavior and exhibits variations according to both age and sex. It offers significant potential for behavioral monitoring and health risk stratification in diverse populations. Article number five. Mid- and Late-term Left Ventricular Diastolic Function After the Ross Procedure. Long-term ventricular mechanics following the Ross procedure for congenital aortic valve disease are not well understood. This procedure, a common surgical option, requires further investigation into its mid- and late-term effects on left ventricular diastolic function. Understanding these long-term functional characteristics is crucial, particularly when comparing outcomes to other surgical repairs for congenital heart lesions. Thank you for listening. Don’t forget to subscribe. Keywords digital biomarker, wild-type amyloid, left atrial remodeling, echocardiography, real-world data, tafamidis, heart rate variability coefficient of variation, long-term mechanics, health risk stratification, left atrioventricular ratio, left ventricular diastolic function, congenital aortic valve disease, surgical repair, Ross procedure, cardiac remodeling, transthyretin amyloid cardiomyopathy, survival, left ventricular remodeling, autonomic fluctuation, behavioral monitoring. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post HRV-CV: A Digital Biomarker for Age, Sex, and Behavior 11/30/25 first appeared on Cardiology Today.